Fig. 2From: Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionationSubgroup analysis of biochemical failure-free survival (BCFFS) according to the NCCN risk groups. a Low risk group. b Intermediate risk group. c High risk group. MHF, moderate hypofractionation; EHF, extreme hypofractionationBack to article page